1 Enzalutamide Prolonged Radiographic Progression-Free Survival Enzalutamide 832 Placebo 801 514 305 256 79 128 20 34 5 5 0 1 0 0 0 Time from Randomization (Months) 0 3 6 9 12 15 18 21 60 50 40 30 20 10 0 90 80 70 100 Enzalutamide Placebo Patients at Risk Estimated median rPFS, months (95% CI): Enzalutamide: NYR (13.8, NYR); Placebo: 3.9 (3.7, 5.4) NYR = Not Yet Reached Exhibit 99.2 |
Enzalutamide Reduced Risk of Death by 29% 2 Estimated median OS, months (95% CI): Enzalutamide: 32.4 (30.1, NYR); Placebo: 30.2 (28.0, NYR) NYR = Not Yet Reached Enzalutamide 872 Placebo 845 863 835 850 781 824 744 797 701 745 644 566 484 395 328 244 213 128 102 33 27 2 2 0 0 Duration of Overall Survival (Months) 60 50 40 30 20 10 0 90 80 70 100 0 3 6 9 12 15 18 21 24 27 30 33 36 Enzalutamide Placebo Patients at Risk Patients still alive at data cut off Enzalutamide: 72%; Placebo: 63% |
Enzalutamide Delayed Median Time to Chemotherapy by 17 Months Enzalutamide 872 Placebo 845 854 734 799 518 751 415 665 324 575 257 388 165 252 103 158 64 78 25 21 9 2 0 0 0 Time to Initiation of Cytotoxic Chemotherapy (Months) 60 50 40 30 20 10 0 90 80 70 100 0 3 6 9 12 15 18 21 24 27 30 33 36 Median Enzalutamide 28.0 months Placebo 10.8 months Enzalutamide Placebo 3 Patients at Risk |